- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
The marketing authorisation for Pramipexole Accord has been withdrawn at the request of the marketing-authorisation holder.
Pramipexole Accord : EPAR - Summary for the public
English (EN) (146.77 KB - PDF)
български (BG) (208.42 KB - PDF)
español (ES) (149.81 KB - PDF)
čeština (CS) (185.16 KB - PDF)
dansk (DA) (144.06 KB - PDF)
Deutsch (DE) (155.06 KB - PDF)
eesti keel (ET) (139.54 KB - PDF)
ελληνικά (EL) (213.09 KB - PDF)
français (FR) (152.96 KB - PDF)
hrvatski (HR) (172.55 KB - PDF)
italiano (IT) (148.43 KB - PDF)
latviešu valoda (LV) (180.6 KB - PDF)
lietuvių kalba (LT) (178.89 KB - PDF)
magyar (HU) (177.23 KB - PDF)
Malti (MT) (187.7 KB - PDF)
Nederlands (NL) (152.9 KB - PDF)
polski (PL) (189.47 KB - PDF)
português (PT) (151.59 KB - PDF)
română (RO) (184.94 KB - PDF)
slovenčina (SK) (178.48 KB - PDF)
slovenščina (SL) (178.52 KB - PDF)
Suomi (FI) (139.62 KB - PDF)
svenska (SV) (144.74 KB - PDF)
Product information
Pramipexole Accord : EPAR - Product Information
English (EN) (1.23 MB - PDF)
български (BG) (1.78 MB - PDF)
español (ES) (1.36 MB - PDF)
čeština (CS) (1.49 MB - PDF)
dansk (DA) (1.31 MB - PDF)
Deutsch (DE) (1.38 MB - PDF)
eesti keel (ET) (1.33 MB - PDF)
ελληνικά (EL) (1.87 MB - PDF)
français (FR) (1.49 MB - PDF)
hrvatski (HR) (1.44 MB - PDF)
íslenska (IS) (1.28 MB - PDF)
italiano (IT) (1.42 MB - PDF)
latviešu valoda (LV) (1.56 MB - PDF)
lietuvių kalba (LT) (1.57 MB - PDF)
magyar (HU) (1.41 MB - PDF)
Malti (MT) (1.6 MB - PDF)
Nederlands (NL) (1.29 MB - PDF)
norsk (NO) (1.25 MB - PDF)
polski (PL) (1.58 MB - PDF)
português (PT) (1.16 MB - PDF)
română (RO) (1.62 MB - PDF)
slovenčina (SK) (1.47 MB - PDF)
slovenščina (SL) (1.47 MB - PDF)
Suomi (FI) (1.33 MB - PDF)
svenska (SV) (1.25 MB - PDF)
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Pramipexole Accord : EPAR - All Authorised presentations
English (EN) (43.27 KB - PDF)
български (BG) (89.32 KB - PDF)
español (ES) (40.78 KB - PDF)
čeština (CS) (51.83 KB - PDF)
dansk (DA) (40.13 KB - PDF)
Deutsch (DE) (39.87 KB - PDF)
eesti keel (ET) (40.21 KB - PDF)
ελληνικά (EL) (84.8 KB - PDF)
français (FR) (41.29 KB - PDF)
hrvatski (HR) (89.03 KB - PDF)
íslenska (IS) (39.65 KB - PDF)
italiano (IT) (38.98 KB - PDF)
latviešu valoda (LV) (71.58 KB - PDF)
lietuvių kalba (LT) (74.02 KB - PDF)
magyar (HU) (74.32 KB - PDF)
Malti (MT) (68.78 KB - PDF)
Nederlands (NL) (36.97 KB - PDF)
norsk (NO) (39.18 KB - PDF)
polski (PL) (53.67 KB - PDF)
português (PT) (40.3 KB - PDF)
română (RO) (74.43 KB - PDF)
slovenčina (SK) (54.97 KB - PDF)
slovenščina (SL) (39.73 KB - PDF)
Suomi (FI) (37.64 KB - PDF)
svenska (SV) (39.84 KB - PDF)
Product details
- Name of medicine
- Pramipexole Accord
- Active substance
- pramipexole dihydrochloride monohydrate
- International non-proprietary name (INN) or common name
- pramipexole
- Therapeutic area (MeSH)
- Parkinson Disease
- Restless Legs Syndrome
- Anatomical therapeutic chemical (ATC) code
- N04BC05
Pharmacotherapeutic group
Anti-Parkinson drugsTherapeutic indication
Pramipexole Accord is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).
Authorisation details
- EMA product number
- EMEA/H/C/002291
Generic
This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.
- Marketing authorisation holder
- Accord Healthcare S.L.U.
Edificio Este Planta 6a
World Trade Center
Moll De Barcelona S/n
08039 Barcelona
SPAIN - Opinion adopted
- 21/07/2011
- Marketing authorisation issued
- 29/09/2011
- Revision
- 10
Assessment history
Pramipexole Accord : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (387.79 KB - PDF)
Pramipexole Accord : EPAR - Public assessment report
English (EN) (550.56 KB - PDF)
CHMP summary of positive opinion for Pramipexole Accord
English (EN) (83.63 KB - PDF)
More information on Pramipexole Accord
Questions and answers on generic medicines
English (EN) (66.45 KB - PDF)
български (BG) (93.16 KB - PDF)
español (ES) (68.3 KB - PDF)
čeština (CS) (87.71 KB - PDF)
dansk (DA) (66.79 KB - PDF)
Deutsch (DE) (67.55 KB - PDF)
eesti keel (ET) (65.21 KB - PDF)
ελληνικά (EL) (91.29 KB - PDF)
français (FR) (68.35 KB - PDF)
hrvatski (HR) (87.8 KB - PDF)
italiano (IT) (67.62 KB - PDF)
latviešu valoda (LV) (111.81 KB - PDF)
lietuvių kalba (LT) (86.76 KB - PDF)
magyar (HU) (85.76 KB - PDF)
Malti (MT) (89.35 KB - PDF)
Nederlands (NL) (66.81 KB - PDF)
polski (PL) (88.51 KB - PDF)
português (PT) (68.32 KB - PDF)
română (RO) (86.9 KB - PDF)
slovenčina (SK) (87.73 KB - PDF)
slovenščina (SL) (84.8 KB - PDF)
Suomi (FI) (66.21 KB - PDF)
svenska (SV) (67.11 KB - PDF)
Public statement on Pramipexole Accord : Withdrawal of the marketing authorisation in the European Union
English (EN) (116.97 KB - PDF)